Drugs /

edp1503

Back to Drugs List

Overview

NCI Definition [1]:
An orally available preparation derived from a single clone of Bifidobacterium spp. with potential immunomodulatory and antineoplastic activities. Upon oral administration, monoclonal microbial EDP1503 colonizes the gut and may, through a not yet fully elucidated mechanism, promote the activation of dendritic cells (DCs), and enhance the induction and infiltration of cytotoxic T-lymphocytes (CTLs) in the tumor microenvironment (TME). Bifidobacterium is a genus of anaerobic, Gram-positive bacteria, with some species being a commensal part of the human gastrointestinal tract and vaginal flora.

Clinical Trials

View Clinical Trials for edp1503

Edp1503 has been investigated in 2 clinical trials, of which 1 is open and 1 is closed. Of the trials investigating edp1503, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open).

Deficient DNA Mismatch Repair (dMMR), ER Negative, and ER No Expression are the most frequent biomarker inclusion criteria for edp1503 clinical trials.

Adenocarcinoma of the gastroesophageal junction, bladder carcinoma, and breast carcinoma are the most common diseases being investigated in edp1503 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Edp1503
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Edp1503
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating edp1503 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
edp-1503, edp 1503, monoclonal microbial edp1503
NCIT ID [1]:
C155907

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.